Clinical Results of Boron Neutron Capture Therapy
The early American clinical trials of Boron Neutron Capture Therapy (hereinafter BNCT) for malignant brain tumors at Brookhaven National Laboratory (BNL) and at the Massachusetts Institute of Technology (MIT) ended in 1961 without having achieved the objectives of the therapy. The aim had been a highly selective destruction of tumor cells while preserving normal organ which harbors the tumor. The last series, 17 cases treated at the MIT Research Reactor, yielded an average survival of 5.7 months. Contrary to expectation, the survival was short and damage to the normal brain (including vascular damage and coagulation necrosis of the brain in the worst case) was found upon autopsy of these patients. BNCT was totally discontinued after 1961. However, it is important to note that the early clinical experience obtained between 1951 and 1961 and described in the literature of that period contributed to my revised therapy conducted after 1968 in Japan, although I had never taken part in the earlier American effort.
KeywordsThermal Neutron Neutron Beam Massachusetts General Hospital Cooperative Study Boron Neutron Capture Therapy
Unable to display preview. Download preview PDF.
- 1.Boron–Neutron Capture Therapy for Tumors,“ ISBN–4–89013–052–7, H. Hatanaka, ed., Nishimura & Co., 1–754–39 Asahimachi–dori, Niigata, Japan (1986).Google Scholar
- 2.H. Hatanaka et al., “Pathological Studies of Maximum Therapeutic Depth by the Current Standard Technique of BNCT,” Third Int. Symp. on Neutron Capture Therapy, Bremen, FRG, 31 May-June 3, 1988.Google Scholar
- 3.T. Kadosawa, A. Takeuchi, T. Nakaichi, T. Matsumoto, T. Nozaki, O. Aizawa, M. Takagaki, M. Moritani, K. Amano, H. Hatanaka, Y. Hayakawa, and T. Inada, “Basic Research in Neutron Capture Therapy (Part I) — Preliminary Study on the Use of D20 for Boron-Neutron Capture Therapy,” Annual Report of Joint Studies at Musashi Institute of Technology Reactor, 12: 9 (1987).Google Scholar
- 5.G. L. Brownell, “A Reassessment of Neutron Capture Therapy in the Treatment of Cerebral Gliomas,” in Proc. Seventh National Cancer Conf., p. 827 (1973).Google Scholar